GlassScriptPhysician profile
Robert J Norris
NPI 1932183845
$786.70
in general payments reported to CMS, 2019-2025
21 companies · $286 in 2025
The $286 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $38.20 · 2020: $119 · 2021: $80.32 · 2023: $83.45 · 2024: $180 · 2025: $286.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $549.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $549.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $178.62 | 2020-2025 | Mounjaro, Zepbound, Kisunla |
| Eisai INC. | $55.85 | 2020-2021 | |
| Astellas Pharma US INC | $51.88 | 2024 | Veozah |
| Abbott Laboratories | $50.73 | 2019-2025 | Proclaim |
| Novo Nordisk INC | $45.89 | 2024-2025 | Wegovy |
| Edwards Lifesciences Corporation | $43.58 | 2023 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Exact Sciences Corporation | $36.15 | 2025 | Cologuard Collection Kit |
| Boston Scientific Corporation | $30.90 | 2025 | Ams 700 |
| Acella Pharmaceuticals, LLC | $30.57 | 2025 | NP Thyroid 60 |
| Otsuka America Pharmaceutical, INC. | $26.51 | 2024 | Rexulti |
| Amgen INC. | $26.28 | 2020-2025 | Prolia, Evenity |
| Sumitomo Pharma America, INC. | $25.58 | 2025 | Gemtesa |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $24.89 | 2025 | Xifaxan |
| Optos, INC. | $24.69 | 2020 | |
| Azurity Pharmaceuticals, INC. | $23.06 | 2023 | Adthyza |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $21.94 | 2020 | |
| Itamar Medical INC | $21.14 | 2024 | Watchpatone |
| Pfizer INC. | $20.17 | 2021 | |
| Kyowa Kirin, INC. | $18.90 | 2024 | Crysvita |
| Glaxosmithkline, LLC. | $16.81 | 2023 | Shingrix, Arexvy |
| Arbor Pharmaceuticals, INC. | $12.56 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Norris listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.